“…Furthermore, this review also reports that a barrier to using patient-reported outcomes (PRO) in clinical practice is the diversity of such instruments. The oncology generic instruments like EORTC QLQ-C30, FACT-G (Stead et al, 1999;Cella et al, 2012) and their disease specific modules, such as EORTC QLQ-MY20, EORTC QLQ-CML24, FACT-Leu (Cocks et al, 2007;Kontodimopoulos et al, 2012;Jones et al, 2013;Efficace et al, 2014;Espinoza-Zamora et al, 2015) which are currently used have been developed and validated to be used in clinical trials. Only one instrument, MYPOS has been recently developed and validated to be used in clinical practice specific for myeloma and Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; ANHL, aggressive non-Hodgkin lymphoma; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; CVI, content validity index; CVR, content validity ratio; EMA, european medicines agency; EORTC QLQ C-30, european organization for the research and treatment of cancer quality of life questionnaire -core 30; EORTC QLQ MY-20, european organization for the research and treatment of cancer quality of life questionnaire -myeloma 20; EORTC QLQ-CML24, european organization for the research and treatment of cancer quality of life questionnaire -chronic myeloid leukaemia-24; FACT-G, functional assessment of cancer therapy: general; FACT-Leu, functional assessment of cancer therapy: leukemia; FDA, food and drug administration; HL, hodgkin lymphoma; HM, hematological malignancy; HM-PRO, hematological malignancy patientreported outcome measure; HRQoL, health-related quality of life; ICC, intra-class correlation; I-CVI, item-content validity index; INHL, indolent non-Hodgkin lymphoma.…”